{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNT.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.05,"timestamp":1745295665586,"preClose":0.051,"halted":0,"volume":1728868,"delay":0,"nameEN":"Syntara Ltd","floatShares":861066441,"shares":1624178055,"eps":-0.00884,"marketStatus":"Trading","change":-0.001,"latestTime":"04-22 14:34:54 AEST","open":0.05,"high":0.05,"low":0.049,"amount":84780,"amplitude":0.019608,"askPrice":0.05,"askSize":76415,"bidPrice":0.049,"bidSize":254690,"shortable":3,"etf":0,"ttmEps":-0.00884,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745301600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.051,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.382882,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":861066441,"roa":"-39.20%","roe":"-89.17%","lyrEps":-0.015849,"volumeRatio":0.382882,"shares":1624178055,"dividePrice":0,"high":0.05,"amplitude":0.019608,"preClose":0.051,"low":0.049,"week52Low":0.014,"pbRate":"4.39","psRate":"9.96","week52High":0.095,"institutionHeld":0,"latestPrice":0.05,"committee":0.538424,"eps":-0.00884,"divideRate":0,"volume":1728868,"delay":0,"ttmEps":-0.00884,"open":0.05,"prevYearClose":0.08,"prevWeekClose":0.051,"prevMonthClose":0.076,"prevQuarterClose":0.076,"fiveDayClose":0.05,"twentyDayClose":0.082,"sixtyDayClose":0.07},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SNT.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522678755","title":"Syntara's Valuation Assumes $750 Million Licensing Deal for Drug Candidate, Eruoz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2522678755","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522678755?lang=en_us&edition=fundamental","pubTime":"2025-03-28 10:48","pubTimestamp":1743130115,"startTime":"0","endTime":"0","summary":"Syntara  valuation assumes a $750 million licensing agreement for its drug candidate, SNT-5505, contingent on its approval in the US and European markets, with the potential for a bigger deal, according to a Thursday note by Euroz Hartleys.SNT-5505 developed for the treatment of bone marrow cancer myelofibrosis, is currently in a Phase 2a clinical trial and interim data showed nearly 50% of patients reporting a greater than 50% reduction in symptom burden after 12 weeks, Euroz said.Euroz estimates that SNT-5505 has a market opportunity exceeding AU$3.6 billion in treating sub-optimally managed myelofibrosis patients across the US and Europe, with the potential to grow over AU$11 billion.SNT-5505's commercial potential is further supported by the increasing merger and acquisition activity and licensing deals in the myelofibrosis space, Euroz added.Euroz believes that the drug candidate has the potential to become a first-line therapy for patients, which would involve a large and expensi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"gpt_icon":0},{"id":"2520153149","title":"Syntara (ASX:SNT) shareholder returns have been fantastic, earning 305% in 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520153149","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520153149?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:00","pubTimestamp":1742328012,"startTime":"0","endTime":"0","summary":"While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-snt/syntara-shares/news/syntara-asxsnt-shareholder-returns-have-been-fantastic-earni","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNT","BK7096","BK4157","SNT.AU"],"gpt_icon":0},{"id":"2520661830","title":"Syntara Develops Drug Candidate for Hypertrophic Scars, Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520661830","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520661830?lang=en_us&edition=fundamental","pubTime":"2025-03-18 13:04","pubTimestamp":1742274291,"startTime":"0","endTime":"0","summary":"Syntara  reported that it is developing a topical anti-fibrotic drug candidate, SNT-9465, as part of its expanded skin scarring program, according to a Tuesday Australian bourse filing.The AU$2 million clinical development plan for SNT-9465, funded from existing cash reserves, is designed to demonstrate the drug's safety and tolerability as well as to study its ability to improve both the appearance and physical properties of hypertrophic scars.A phase 1a dose escalation study in healthy volunteers will be conducted to determine the optimal dose for complete lysyl oxidase inhibition. This will be followed by an open-label phase 1b extension, which will assess improvements in the appearance and composition of hypertrophic scars that are less than 24 months old, after three months of daily treatment.It expects the results to come in the first half of 2026.Meanwhile, The Fiona Wood Foundation and the University of Western Australia will conduct an exploratory clinical trial on keloid scar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","XJO.AU","SNT.AU","BK7096"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7502","SGXZ23171101.USD","NEU.AU","XKO.AU","LU1169590202.USD","CSL","BK7096","SNT.AU","DXB.AU","BK7511","IMM.AU","BK7501","SG9999004303.SGD","LU1169589451.USD","XAO.AU","BOT.AU","TLX.AU","LU0728928796.USD","OPT.AU","CSL.AU","XJO.AU","BK4086","CVB.AU","BK7007","BK7508","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[]}}